Efficacy of Treatments in Reducing Inflammatory Lesion Count in Rosacea: A Systematic Review
Open Access
- 28 May 2024
- journal article
- research article
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 28 (4) , 352-359
Abstract
Introduction: Rosacea is a chronic inflammatory skin condition affecting approximately 5.5% of the global population. Patients present heterogeneously with a mix of features in the central facial region, of which papules and pustules are considered to be a major feature. The identification of effective treatments for reducing inflammatory lesions in rosacea can alleviate the psychosocial burden that many rosacea patients experience, including reduced self-esteem, anxiety, and social withdrawal. The objective of this systematic review is to determine the effectiveness of topical and systemic therapies in reducing lesion count in rosacea patients. Methods/Results: Medline, Embase, and Cochrane CENTRAL databases were searched, resulting in the inclusion of 43 clinical trials reporting on a total of 18,347 rosacea patients. The most well-studied treatments include ivermectin, metronidazole, azelaic acid, minocycline, and doxycycline. Oral isotretinoin was the most effective treatment in reducing inflammatory lesions and may be recommended for severe recalcitrant cases of rosacea. Conclusions: Several topical and systemic therapies have demonstrated efficacy in reducing inflammatory lesion count in rosacea patients, with mechanisms of action centred around suppressing inflammation and killing Demodex folliculorum mites. Additional research is required to determine effective combination therapies in rosacea.Keywords
This publication has 58 references indexed in Scilit:
- Topical ivermectin-metronidazole gel therapy in the treatment of blepharitis caused by Demodex spp.: A randomized clinical trialContact Lens and Anterior Eye, 2021
- A Phase II, Randomized, Double-Blind Clinical Study Evaluating the Safety, Tolerability, and Efficacy of a Topical Minocycline Foam, FMX103, for the Treatment of Facial Papulopustular RosaceaAmerican Journal of Clinical Dermatology, 2018
- Superior Efficacy with Ivermectin 1% Cream Compared to Metronidazole 0.75% Cream Contributes to a Better Quality of Life in Patients with Severe Papulopustular Rosacea: A Subanalysis of the Randomized, Investigator-Blinded ATTRACT StudyDermatology and Therapy, 2016
- Rosacea: Current state of epidemiologyJournal of the American Academy of Dermatology, 2013
- Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gelJournal of the American Academy of Dermatology, 2013
- Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosaceaJournal of the American Academy of Dermatology, 2007
- A Comparison of 15% Azelaic Acid Gel and 0.75% Metronidazole Gel in the Topical Treatment of Papulopustular RosaceaArchives of Dermatology, 2003
- Randomized Placebo-controlled Trial of Metronidazole 1% Cream with Sunscreen SPF 15 in Treatment of RosaceaJournal of Cutaneous Medicine and Surgery, 2002
- Effect of Treatment of Helicobacter pylori Infection on RosaceaArchives of Dermatology, 1999
- A Double-Blind Randomised Study of Metronidazole (Flagyl®) 1% Cream in the Treatment of Acne RosaceaClinical Drug Investigation, 1990